• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful Treatment of Osimertinib Resistance in an EGFR-Mutant Lung Cancer Patient With a Rare STRN3-ALK Fusion Using Brigatinib and Osimertinib.

作者信息

Kuo Chia-Yu, Lai Wei-An, Lee Tai-Huang, Yang Chih-Jen

机构信息

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

Department of Pathology, Kaohsiung Medical University, Kaohsiung, Taiwan.

出版信息

Kaohsiung J Med Sci. 2025 Jul;41(7):e70021. doi: 10.1002/kjm2.70021. Epub 2025 May 8.

DOI:10.1002/kjm2.70021
PMID:40342254
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12412511/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/320c/12412511/1541af276151/KJM2-41-e70021-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/320c/12412511/1541af276151/KJM2-41-e70021-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/320c/12412511/1541af276151/KJM2-41-e70021-g001.jpg

相似文献

1
Successful Treatment of Osimertinib Resistance in an EGFR-Mutant Lung Cancer Patient With a Rare STRN3-ALK Fusion Using Brigatinib and Osimertinib.使用布加替尼和奥希替尼成功治疗一名患有罕见STRN3-ALK融合的EGFR突变肺癌患者的奥希替尼耐药性
Kaohsiung J Med Sci. 2025 Jul;41(7):e70021. doi: 10.1002/kjm2.70021. Epub 2025 May 8.
2
Alectinib efficacy in advanced lung adenocarcinoma with coexistence of a novel ALK-MTUS2 and STRN3-ALK double fusion: A case report and literature review.阿来替尼在同时存在新型ALK-MTUS2和STRN3-ALK双重融合的晚期肺腺癌中的疗效：一例报告及文献综述
Oncol Lett. 2025 Jul 7;30(3):432. doi: 10.3892/ol.2025.15178. eCollection 2025 Sep.
3
Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK-positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib.阿来替尼和布加替尼耐药后lorlatinib 颅内治疗成功：布加替尼中枢神经系统穿透率的影响。
Thorac Cancer. 2024 Aug;15(23):1772-1775. doi: 10.1111/1759-7714.15395. Epub 2024 Jun 24.
4
Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer.唾液酸转移酶 ST3GAL4 赋予奥希替尼耐药性，并为克服非小细胞肺癌的耐药性提供策略。
Cancer Lett. 2024 Apr 28;588:216762. doi: 10.1016/j.canlet.2024.216762. Epub 2024 Feb 24.
5
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status.
Clin Lung Cancer. 2025 Jun 6. doi: 10.1016/j.cllc.2025.05.016.
6
Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.洛拉替尼在瑞典一线治疗间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌成人患者中的成本效益分析。
Appl Health Econ Health Policy. 2023 Jul;21(4):661-672. doi: 10.1007/s40258-023-00807-7. Epub 2023 May 12.
7
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.在真实世界中，表皮生长因子受体（EGFR）突变的非小细胞肺癌患者序贯接受酪氨酸激酶抑制剂和奥希替尼治疗后的良好生存结果。
J Cancer Res Clin Oncol. 2023 Sep;149(11):9243-9252. doi: 10.1007/s00432-023-04839-3. Epub 2023 May 18.
8
Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma.阿帕替尼联合奥希替尼对EGFR T790M阳性肺腺癌的影响
Transl Cancer Res. 2019 Sep;8(5):2151-2163. doi: 10.21037/tcr.2019.09.35.
9
Pharmacoeconomic Analysis of Brigatinib versus Alectinib in First‑Line Treatment of Anaplastic Lymphoma Kinase‑Positive Advanced Non‑Small‑Cell Lung Cancer in China.在中国，布加替尼与阿来替尼用于一线治疗间变性淋巴瘤激酶阳性晚期非小细胞肺癌的药物经济学分析
Oncol Ther. 2025 Jul 24. doi: 10.1007/s40487-025-00361-3.
10
Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer.靶向WEE1以克服EGFR突变型肺癌中ARID1A突变驱动的奥希替尼耐药性。
J Thorac Oncol. 2025 Jun 13. doi: 10.1016/j.jtho.2025.06.007.

本文引用的文献

1
EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature.EML4-ALK融合作为奥希替尼的耐药机制及其通过奥希替尼和阿来替尼成功治疗：病例报告及文献综述
Clin Lung Cancer. 2020 Nov;21(6):e597-e600. doi: 10.1016/j.cllc.2020.05.016. Epub 2020 May 23.
2
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.奥希替尼治疗 EGFR 突变型非小细胞肺癌的耐药机制。
Br J Cancer. 2019 Oct;121(9):725-737. doi: 10.1038/s41416-019-0573-8. Epub 2019 Sep 30.
3
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
4
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.奥希替尼或铂类培美曲塞用于治疗表皮生长因子受体T790M阳性肺癌
N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.
5
Identification of a recurrent STRN/ALK fusion in thyroid carcinomas.甲状腺癌中一种复发性STRN/ALK融合的鉴定。
PLoS One. 2014 Jan 27;9(1):e87170. doi: 10.1371/journal.pone.0087170. eCollection 2014.